Literature DB >> 18828727

Robust hepatic gene silencing for functional studies using helper-dependent adenoviral vectors.

Rafaela Ruiz1, Scott R Witting, Romil Saxena, Núria Morral.   

Abstract

RNA interference is currently envisioned as the basis of gene function and drug target validation studies. This novel technology has the advantage of providing a remarkably faster tool for gene silencing than traditional transgenic animal methodologies. In vivo administration of short interfering RNA (siRNA) typically results in reduced target gene expression for approximately 1 week. Viral vectors offer the possibility to express constitutive levels of short hairpin RNA (shRNA) so that the effects of knocking down the target gene can be studied for a few weeks, rather than a few days. Helper-dependent vectors have a significant advantage over previous generations of adenoviral vectors because of their much higher cloning capacity, potential for long-term transgene expression, and enhanced safety profiles on administration in vivo. Therefore, this advanced type of vector is an excellent tool to carry out in vivo studies directed at constitutive expression of shRNA. Here we show it is possible to obtain more than 90% target gene knockdown in an animal model of type 2 diabetes for several weeks, thereby consolidating this technology as an alternative to generating liver-specific knockout animals.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18828727      PMCID: PMC2855247          DOI: 10.1089/hum.2008.081

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  37 in total

1.  Packaging cell lines for generating replication-defective and gutted adenoviral vectors.

Authors:  Jeffrey S Chamberlain; Catherine Barjot; Jeannine Scott
Journal:  Methods Mol Med       Date:  2003

2.  Improved system for helper-dependent adenoviral vector production.

Authors:  Donna Palmer; Philip Ng
Journal:  Mol Ther       Date:  2003-11       Impact factor: 11.454

3.  A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase.

Authors:  S Kochanek; P R Clemens; K Mitani; H H Chen; S Chan; C T Caskey
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

4.  The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12.

Authors:  J V Maizel; D O White; M D Scharff
Journal:  Virology       Date:  1968-09       Impact factor: 3.616

5.  Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector.

Authors:  K Mitani; F L Graham; C T Caskey; S Kochanek
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-25       Impact factor: 11.205

6.  Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes.

Authors:  Jay D Horton; Nila A Shah; Janet A Warrington; Norma N Anderson; Sahng Wook Park; Michael S Brown; Joseph L Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-25       Impact factor: 11.205

7.  Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells.

Authors:  R Kumar-Singh; J S Chamberlain
Journal:  Hum Mol Genet       Date:  1996-07       Impact factor: 6.150

8.  Adenovirus-mediated expression of glucokinase in the liver as an adjuvant treatment for type 1 diabetes.

Authors:  Núria Morral; Robert McEvoy; Hengjiang Dong; Marcia Meseck; Jennifer Altomonte; Swan Thung; Savio L C Woo
Journal:  Hum Gene Ther       Date:  2002-09-01       Impact factor: 5.695

9.  An albumin enhancer located 10 kb upstream functions along with its promoter to direct efficient, liver-specific expression in transgenic mice.

Authors:  C A Pinkert; D M Ornitz; R L Brinster; R D Palmiter
Journal:  Genes Dev       Date:  1987-05       Impact factor: 11.361

10.  Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis.

Authors:  K J Fisher; H Choi; J Burda; S J Chen; J M Wilson
Journal:  Virology       Date:  1996-03-01       Impact factor: 3.616

View more
  8 in total

1.  Vector and helper genome rearrangements occur during production of helper-dependent adenoviral vectors.

Authors:  Miwon Ahn; Aisha Gamble; Scott R Witting; Jack Magrisso; Sneha Surendran; Silvana Obici; Núria Morral
Journal:  Hum Gene Ther Methods       Date:  2013-02       Impact factor: 2.396

2.  Sterol regulatory element-binding protein-1 (SREBP-1) is required to regulate glycogen synthesis and gluconeogenic gene expression in mouse liver.

Authors:  Rafaela Ruiz; Victoria Jideonwo; Miwon Ahn; Sneha Surendran; Vincent S Tagliabracci; Yongyong Hou; Aisha Gamble; Janos Kerner; José M Irimia-Dominguez; Michelle A Puchowicz; Anna DePaoli-Roach; Charles Hoppel; Peter Roach; Núria Morral
Journal:  J Biol Chem       Date:  2014-01-07       Impact factor: 5.157

3.  Constitutive expression of short hairpin RNA in vivo triggers buildup of mature hairpin molecules.

Authors:  M Ahn; S R Witting; R Ruiz; R Saxena; Núria Morral
Journal:  Hum Gene Ther       Date:  2011-10-04       Impact factor: 5.695

4.  Helper-Dependent Adenoviral Vectors.

Authors:  Amanda Rosewell; Francesco Vetrini; Philip Ng
Journal:  J Genet Syndr Gene Ther       Date:  2011-10-29

5.  Comparative nucleic acid transfection efficacy in primary hepatocytes for gene silencing and functional studies.

Authors:  Jae-Seung Park; Sneha Surendran; Lisa M Kamendulis; Núria Morral
Journal:  BMC Res Notes       Date:  2011-01-18

6.  Gene therapy with helper-dependent adenoviral vectors: current advances and future perspectives.

Authors:  Francesco Vetrini; Philip Ng
Journal:  Viruses       Date:  2010-09-03       Impact factor: 5.818

Review 7.  Adenovirus and miRNAs.

Authors:  Elena Carnero; James D Sutherland; Puri Fortes
Journal:  Biochim Biophys Acta       Date:  2011-05-17

8.  Impact of silencing hepatic SREBP-1 on insulin signaling.

Authors:  Victoria Jideonwo; Yongyong Hou; Miwon Ahn; Sneha Surendran; Núria Morral
Journal:  PLoS One       Date:  2018-05-03       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.